Цисплатин "Ебеве"

Основна информация

  • Търговско наименование:
  • Цисплатин "Ебеве" (Cisplatin "Ebewe")
  • дозиране:
  • 0,5 mg/ml - 20 ml; - 50 ml; - 1
  • Лекарствена форма:
  • концентрат за инфузионен разтвор
  • Композиция:
  • концентрат за инфузионен разтвор 0,5 mg/ml - 20 ml; - 50 ml; - 1
  • Използвай за:
  • Хората
  • Вид на лекарството:
  • алопатични наркотици

Документи

Локализация

  • Предлага се в:
  • Цисплатин "Ебеве" (Cisplatin "Ebewe")
    България
  • Език:
  • български

Друга информация

Състояние

  • Източник:
  • Изпълнителна агенция по лекарствата - Bulgarian Drug Agency - Bulgaria
  • Последна актуализация:
  • 09-08-2016

Листовка за пациента

18-5-2018

Keytruda (pembrolizumab) or Tecentriq (atezolizumab): FDA Alerts Health Care Professionals and Investigators: FDA Statement - Decreased Survival in Some Patients in Clinical Trials Associated with Monotherapy

Keytruda (pembrolizumab) or Tecentriq (atezolizumab): FDA Alerts Health Care Professionals and Investigators: FDA Statement - Decreased Survival in Some Patients in Clinical Trials Associated with Monotherapy

Early reviews found patients in the monotherapy arms of both trials with PD-L1 low status had decreased survival compared to patients who received cisplatin- or carboplatin-based chemotherapy.

FDA - U.S. Food and Drug Administration

22-12-2017

CISPLATIN Injection, Solution [Teva Parenteral Medicines, Inc.]

CISPLATIN Injection, Solution [Teva Parenteral Medicines, Inc.]

Updated Date: Dec 22, 2017 EST

US - DailyMed

29-9-2017

CISPLATIN Injection, Solution [Alvogen Inc.]

CISPLATIN Injection, Solution [Alvogen Inc.]

Updated Date: Sep 29, 2017 EST

US - DailyMed

16-8-2017

CISPLATIN Injection, Solution [Fresenius Kabi USA, LLC]

CISPLATIN Injection, Solution [Fresenius Kabi USA, LLC]

Updated Date: Aug 16, 2017 EST

US - DailyMed

14-8-2017

Carboplatin

Carboplatin

Carboplatin is an anti-cancer medication indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin injection and cyclophosphamide. Carboplatin injection is also indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin.

US - RxList

2-8-2017

CISPLATIN Injection, Solution [Athenex Pharmaceutical Division, LLC.]

CISPLATIN Injection, Solution [Athenex Pharmaceutical Division, LLC.]

Updated Date: Aug 2, 2017 EST

US - DailyMed